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To the Editor 
Cardiovascular disease (CVD) is common in patients with chronic obstructive 
pulmonary disease (COPD) (1-4), yet it is unclear whether its presence increases the 
incidence of acute exacerbations (AECOPD) or the risk of death. Observational 
studies have shown that COPD is associated with a 2-5 times higher risk of 
ischaemic heart disease (IHD), cardiac dysrhythmia, heart failure, diseases of the 
pulmonary circulation, and diseases of the arteries, compared with non-COPD 
populations (4,5). A prospective evaluation of COPD exacerbations in patients with 
comorbid IHD from the London COPD Cohort reported longer duration but not an 
increased frequency of AECOPD in patients with IHD (6). 
This prospective study was designed to test the hypothesis that the presence of CVD 
increases the risk of AECOPD and/or death in COPD patients recruited in a primary 
care setting. 
Methods 
The ACCESS study (Assessment of Comorbidities in COPD in European 
Symptomatic Subjects; NCT01516528; 115058 study) was a prospective, 
longitudinal, observational, non-drug interventional, two-year study in COPD patients 
enrolled from primary care in Belgium, France, Germany, the Netherlands, Poland, 
and Spain.  Patients, visiting their general practitioner (GP) for any reason, were 
invited to participate if they were ≥40 years old, current or ex-smoker (smoking 
history of ≥10 pack-years), a minimum of 12 months of prior history of COPD, and a 
forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) post-
bronchodilator ratio <0.70. Patients with a primary diagnosis of asthma, pulmonary 
fibrosis, asbestosis, any cancer or clinically significant bronchiectasis were excluded. 
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Patients were followed up for 27 months through clinic visits at screening (-3 
months), baseline (0 months), 12 months and 24 months, and by phone at 3, 6, 9, 
15, 18 and 21 months. Written informed consent was obtained from all subjects and 
the study was approved by independent ethics committees as per the requirements 
in each country.   
The prevalence of CVD at baseline was defined using a composite measure with 
previously published criteria (7). The primary outcome was the annual rate of 
moderate-severe AECOPD during the 24-month follow-up period. Moderate 
AECOPD was defined as a worsening of symptoms that required oral corticosteroids 
and/or antibiotics, whilst severe exacerbations were defined as those that included 
hospitalization. Mortality was a secondary outcome; details of patient deaths were 
obtained from the GP. 
To derive event rates and test associations, we applied multivariable negative 
binomial regression and Cox proportional hazards regression models, respectively. 
All analysis was pre-specified except hospitalizations and mortality outcome 
modeling which were post-hoc.  
Results 
2,887 evaluable patients were included in this analysis. Their mean age was 66 
years, 70% were male, and 47% were current smokers with a mean post-
bronchodilator FEV1% predicted of approximately 60% (Table 1). The mean number 
of moderate-severe AECOPD episodes in the previous year was 0.61 (95% CI: 0.57, 
0.64); for severe AECOPD: 0.08 (95% CI:  0.07, 0.09). At baseline, COPD patients 
with CVD (1375, 48%) were older and more likely to be ex-smokers, but had similar 
airflow limitation and history of exacerbations to those without CVD.  
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Over 24 months, there was no difference in the annualized rate of AECOPD between 
those with or without CVD (adjusted rate per patient: 0.63 (95% CI: 0.57, 0.69) vs. 
0.63 (95% CI: 0.58, 0.69); the Rate Ratio was 0.99 (95% CI: 0.88,1.11) (Table 2). 
Male sex, lower post-bronchodilator FEV1 % predicted, and higher CAT score, but 
not older age, were significantly independently associated with a higher overall rate 
of exacerbations. Addition of history of AECOPD events in the 12 months prior to 
study baseline into models was significantly associated with the rate during the 
study, but it didn’t change the effect of CVD on this outcome (Rate Ratio: 1.01 [95% 
CI: 0.90,1.12]). Additionally, a sensitivity analysis for each CVD diagnosis from the 
composite CVD definition, did not show any relationship between individual CV 
diseases and the incidence of AECOPD. 
The unadjusted annual rate of severe exacerbations (requiring hospitalization) was 
51% higher in patients with CVD than those with no CVD (Rate Ratio 1.51 [95% CI: 
1.16; 1.97], p=0.003)). In the adjusted multivariable model, this trend was not 
statistical significant (Rate Ratio 1.14 (95% CI: 0.87; 1.50) (Table 2). 
The crude mortality rate was greater in patients with CVD compared with no CVD 
(3.0 events per 100 patient years [95% CI: 2.3, 3.6] vs. 1.5 [95% CI: 1.1, 2.0]), 
however, this association was attenuated in the multivariable model (Hazard Ratio in 
patients with/without CVD: 1.26 (95% CI: 0.85, 1.87) due to statistically significant 
effects of age, gender and COPD clinical characteristics. 
Discussion:  
This is the first large scale study to prospectively evaluate the relationship between 
CVD and exacerbation rates and mortality in a well characterized cohort of COPD 
patients. Although, on average, the patients were relatively mild in terms of lung 
function, CAT score and exacerbation rate, the cohort did contain the whole range of 
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disease severity. We found that the presence of CVD was not independently 
associated with an increased risk of exacerbations or death. This finding was not 
expected in view of prior evidence that there was a link (8-10). There are at least two 
reasons to explain this difference. Some earlier studies had methodological 
limitations, for example, two were retrospective and used data extracted from routine 
electronic medical records. Furthermore, it is also important to understand temporal 
associations and mechanisms of causality. For example, patients hospitalized for 
AECOPD are at increased risk of myocardial infarction following admission (11,12), 
and case series data provide evidence of a link through viral infections, which may 
trigger both AECOPD and vascular events (13,14). 
It is conceivable that within this primary care population, there was an insufficient 
number of patients of a particular phenotype in whom a link does exist, or patients 
did not have sufficiently severe COPD to demonstrate the link, but the sample was 
large and the rate ratio was very close to 1.0, so the likelihood of this being a factor 
is low. We conclude that there is little or no evidence that the presence of CVD in 
COPD patients increases the risk of exacerbations or death, but it may increase the 
risk of hospitalization. 
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Table 1: Baseline characteristics at the screening visit 
 Patients 
with CVD 
(N=1375) 
Patients 
without CVD 
(N=1512) 
 
Total 
(N=2887) 
Age (years), mean (SD)  69.7 (8.7) 62.9 (9.9) 66.1 (10.0) 
Male, n (%)  1050 (76) 964 (64) 2014 (70) 
Body mass index, mean kg/m2   
(SD)  
27.9 (5.1) 26.5 (5.3) 27.2 (5.2) 
Current smoker, n (%)  534 (39) 820 (54) 1354 (47) 
CAT score*, mean (SD)   15.6 (7.7) 14.5 (7.7) 15.0 (7.7) 
Mean post-bronchodilator FEV1 % 
predicted (SD)  
58.8 (19.1) 60.0 (19.8) 59.4 (19.5) 
GOLD grade airflow limitation 
1 - mild 
2 - moderate 
3 - severe 
4 - very severe 
 
183 (13.3) 
736 (53.5) 
376 (27.3) 
80 (5.8) 
 
238 (15.7) 
779 (51.5) 
393 (26.0) 
102 (6.7) 
 
421 (14.6) 
1515 (52.5) 
769 (26.6) 
182 (6.3) 
GOLD 2016 group†, n (%) 
A – low symptom/low risk 
B – high symptom/low risk 
C – low symtoms/high risk 
D – high symptom/high risk 
 
228 (17) 
548 (40) 
91 (7) 
505 (37) 
 
337 (22) 
549 (37) 
119 (8) 
497 (33) 
 
565 (20) 
1097 (38) 
210 (7) 
1002 (35) 
COPD exacerbations in12 
months prior to baseline 
Moderate-severe  
N (%) patients with ≥1 event 
Mean (95% CI) 
Events requiring hospitalization 
N (%) patients with ≥1 event 
Mean (95% CI) 
 
 
 
516 (38) 
0.60 (0.54;0.65) 
 
113 (8) 
0.11 (0.09;0.14) 
 
 
 
570 (38) 
0.61 (0.56;0.66) 
 
68 (4) 
0.05 (0.04;0.07) 
 
 
 
1086 (38) 
0.61 (0.57;0.64) 
 
181 (6) 
0.08(0.07;0.09) 
*CAT was assessed at the baseline visit; †Combined assessment based on CAT as a 
symptom measure according to GOLD 2016. CVD: cardiovascular disease; CAT: COPD 
Assessment Test; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 sec; 
GOLD: Global Initiative for Chronic Obstructive Lung Disease; SD: standard deviation; CI: 
confidence interval 
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Table 2:  Adjusted annual rate of moderate-severe COPD exacerbations and 
hospitalizations due to COPD after 24 months of follow-up - Negative binomial 
regression analysis including covariates 
 CVD (N=1375) No CVD (N=1512) 
Adjusted annual rate per patient of 
moderate-severe exacerbations (95% CI) 
 
0.63 (0.57;0.69) 
 
0.63 (0.58;0.69) 
Rate Ratio in patients with CVD / without 
CVD (95% CI) 
Effect of covariates; parameter estimate (p-
value): 
 Age 
 Gender (female) 
 Smoking status (current smoker) 
 Post-bronchodilator FEV1 % 
predicted 
 CAT score 
0.99 (0.88;1.11) 
 
 
 
0.0057 (0.074) 
0.1788 (0.004) 
- 0.0997 (0.093) 
- 0.0142 (<0.001) 
 
0.0368 (<0.001) 
Adjusted annual rate per patient of 
hospitalizations due to COPD (95% CI) 
 
0.05 (0.04;0.06) 
 
0.04 (0.04;0.06) 
Rate Ratio in patients with CVD / without 
CVD (95% CI) 
Effect of covariates (p-value) 
 Age 
 Gender (female) 
 Smoking status (current smoker) 
 Post-bronchodilator FEV1 % 
 predicted 
 CAT score 
1.14 (0.87;1.50) 
 
 
0.0395 (<0.001) 
0.2738 (0.059) 
0.0416 (0.767) 
-0.0381 (<0.001) 
 
0.0725 (<0.001) 
Models were also adjusted for the country effect. 
CVD: cardiovascular disease; CAT: COPD Assessment Test; FEV1: forced expiratory 
volume in 1 sec; CI: confidence interval 
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